In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth

International Journal of Pharmaceutics

Volumn 392, Issue 1-2, 2010, Pages 51-56

  Lee, Ju Young ^a,b   Kim, Kyung Sook ^a   Kang, Yun Mi ^c   Kim, E Sle ^c   Hwang, Sung Joo ^b   Lee, Hai Bang ^c   Min, Byoung Hyun ^c   Kim, Jae Ho ^c   Kim, Moon Suk ^a,c  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Chungnam National University   (South Korea)

^c Ajou University   (South Korea)

Author keywords

Injectable in situ gel; Intratumoral injection; Paclitaxel; Tumors

Indexed keywords

COPOLYMER; MACROGOL; PACLITAXEL; POLYCAPROLACTONE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; GEL; HISTOPATHOLOGY; IN VIVO STUDY; LIQUID; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ROOM TEMPERATURE; SOLID TUMOR; SUBCUTANEOUS TISSUE TUMOR; TISSUE NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOCOMPATIBLE MATERIALS; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; GELS; INJECTIONS, INTRALESIONAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, HAIRLESS; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; POLYESTERS; POLYETHYLENE GLYCOLS; SOLUBILITY; TEMPERATURE; VISCOSITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952740817     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.033     Document Type: Article

References (30)

1. Ahn H.H., Kim K.S., Lee J.H., Lee J.Y., Lee I.W., Chun H.J., Kim J.H., Lee H.B., Kim M.S. In Vivo Osteogenic Differentiation of Human Adipose-Derived Stem Cells in an Injectable In Situ-Forming Gel Scaffold. Tissue Eng. Part A 2009, 15:1821-1832.
2. Bajpai A.K., Shukla S.K., Bhanu S., Kankane S. Responsive polymers in controlled drug delivery. Prog. Polym. Sci. 2008, 33:1088-1118.
3. Benotti P., Steele Patterns of recurrent colorectal cancer and recovery surgery. Cancer 1992, 70:1409-1413.
4. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., Levy-Nissenbaum E., Aleksandar R.F., Langer R., Farokhzad O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
5. Cho K.J. Targeted Delivery of Nanoparticles for Cancer Treatment. Tissue Eng. Reg. Med. 2008, 5:172-179.
6. Chun C., Lee S.M., Kim S.Y., Yang H.K., Song S.C. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials 2009, 30:2349-2360.
7. Chvapil M. Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens. Anticancer Drugs 2005, 16:201-210.
8. Devalapally H., Duan Z., Seiden M.V., Amiji M.M. Paclitaxel and ceramide coadministration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int. J. Cancer 2007, 121:1830-1838.
9. de Bree E., Theodoropoulos P.A., Rosing H., Michalakis J., Romanos J., Beijnen J.H., Tsiftsis D.D. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat. Rev. 2006, 32:471-482.
10. Ding L., Lee T., Wang C.H. Fabrication of monodispersed Taxol-loaded particles using electrohydrodynamic atomization. J. Control. Rel. 2005, 102:395-413.
11. Fjällskog M.L., Frii L., Bergh J. Is Cremophor EL, solvent for paclitaxel, cytotoxic?. The Lancet 1993, 342:873.
12. Goldberg E.P., Hadba A.R., Almond B.A., Marottam J.S. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J. Pharm. Pharmacol. 2002, 54:159-180.
13. Hyun H., Kim Y.H., Song I.B., Lee J.W., Kim M.S., Khang G., Park K., Lee H.B. In vitro and in vivo release of albumin using biodegradable MPEG-PCL diblock copolymer as an in situ gel forming carrier. Biomacromolecules 2007, 8:1093-1100.
14. Kim M.S., Hyun H., Seo K.S., Cho Y.H., Khang G., Lee H.B. Preparation and characterization of MPEG-PCL diblock copolymers with thermo-responsive sol-gel-sol behavior. J. Polym. Sci. Part A: Polym. Chem. 2006, 44:5413-5423.
15. Kim M.S., Kim S.K., Kim S.H., Hyun H.H., Khang G., Lee H.B. In vivo Osteogenic Differentiation of Rat Bone Marrow Stromal Cells in Thermosensitive MPEG-PCL Diblock Copolymer Gel. Tissue Eng. 2006, 12:2863-2873.
16. Lee S.H., Oh J.M., Son J.S., Khang G., Lee B., Park Y.H., Ko J.H., Chun H.J., Kim J.H., Lee H.B., Kim M.S. Hydrogel Nanoparticles for Drug Delivery System. Tissue Eng. Reg. Med. 2009, 6:57-62.
17. Ong B.Y., Ranganath S.H., Lee L.Y., Lu F., Lee H.S., Sahinidis N.V., Wang C.H. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials 2009, 30:3189-3196.
18. Park J.H., Lee S., Kim J.H., Park K., Kim K., Kwon I.C. Polymeric nanomedicine for cancer therapy. Prog. Polym. Sci. 2008, 33:113-137.
19. Parvez T. Present trend in the primary treatment of aggressive malignant glioma: glioblastoma multiforme. Technol. Cancer Res. Treat. 2008, 7:241-248.
20. Pawar R., Shikanov A., Vaisman B., Domb A.J. Intravenous and regional paclitaxel formulations. Curr. Med. Chem. 2004, 11:397-402.
21. Ranganath S.H., Wang C.H. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials 2008, 29:2996-3003.
22. Rossi C.R., Mocellin S., Pilati P., Foletto M., Quintieri L., Palatini P., Lise M. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg. Oncol. Clin. N. Am. 2003, 12:781-794.
23. Sasatsu M., Onishi H., Machida Y. Preparation and biodisposition of methoxypolyethylene glycol amine-poly(DL-lactic acid) copolymer nanoparticles loaded with pyrene-ended poly(DL-lactic acid). Int. J. Pharm. 2008, 358:271-277.
24. Singh P., Rathinasamy K., Mohan R., Panda D. Microtubule assembly dynamics: an attractive target for anticancer drugs. IUBMB Life 2008, 60:368-375.
25. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 2002, 235:179-192.
26. Spencer C.M., Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994, 48:794-847.
27. Springate C.M., Jackson J.K., Gleave M.E., Burt H.M. Clusterin antisense complexed with chitosan for controlled intratumoral delivery. Int. J. Pharm. 2008, 350:53-64.
28. Ta H.T., Dass C.R., Dunstan D.E. Injectable chitosan hydrogels for localised cancer therapy. J. Control. Rel. 2008, 126:205-216.
29. Terwogt J.M., Nuijen B., Huinink W.W., Beijnen J.H. Alternative formulations of paclitaxel. Cancer Treat. Rev. 1997, 23:87-95.
30. Vintiloiu A., Leroux J.C. Organogels and their use in drug delivery - A review. J. Control. Rel. 2008, 125:179-192.